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Abstract: Piglets are susceptible to infections in early life and around weaning due to rapid
environmental and dietary changes. A compelling target to improve pig health in early life is
diet, as it constitutes a pivotal determinant of gut microbial colonization and maturation of the
host’s immune system. In the present study, we investigated how supplementation of yeast-derived
β-glucans affects the gut microbiota and immune function pre- and post-weaning, and how these
complex systems develop over time. From day two after birth until two weeks after weaning, piglets
received yeast-derived β-glucans or a control treatment orally and were subsequently vaccinated
against Salmonella Typhimurium. Faeces, digesta, blood, and tissue samples were collected to study
gut microbiota composition and immune function. Overall, yeast-derived β-glucans did not affect
the vaccination response, and only modest effects on faecal microbiota composition and immune
parameters were observed, primarily before weaning. This study demonstrates that the pre-weaning
period offers a ‘window of opportunity’ to alter the gut microbiota and immune system through diet.
However, the observed changes were modest, and any long-lasting effects of yeast-derived β-glucans
remain to be elucidated.
Keywords: β-glucans; porcine; gastro-intestinal tract; gut microbiota; immune system; early life
1. Introduction
Early in life and during weaning, pigs are at risk of developing diseases which compromise animal
welfare and have major economic consequences for the pig industry. The early postnatal and weaning
periods are critical, as the gastrointestinal (GI) system and the immune system are still undergoing
major changes [1,2]. Microbial colonization of the gut starts at birth with the transfer of maternal
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vaginal, gut, and skin microbiota to the piglet [3]. Moreover, diet and environmental exposures
(e.g., housing conditions) are major contributors to subsequent microbial colonization of the gut and
development of the immune system [4,5]. It is now recognized that pathogen and environmental
exposures impact on the microbial community later in life and that early-life colonization of the
mammalian host’s mucosal surfaces plays an important role in the maturation of the host’s immune
system [6,7]. For example, many studies in different countries have confirmed that growing up on a
farm has a protective effect on asthma and allergies in humans [8]. Another study in mice has shown
that low dose treatment with antibiotics can induce obesity later in life. Interestingly, the induction of
obesity was not correlated with the antibiotic treatment itself, but with the changes in microbiota [9].
Similar results have been observed for early-life antibiotic treatment in pigs [10]. This implies that
changes and interventions in early life, affecting either the microbiota or the immune system, may have
long-lasting effects on health, welfare and performance.
Diet constitutes a pivotal determinant of gut microbial colonization and development, which makes
it a compelling target for modulation of the gut microbiota and immune function [11]. Thus, dietary
interventions (e.g., prebiotics and probiotics) attracted much interest after the EU wide ban on
antimicrobial growth promotors (AMGPs) for production animals in 2006. The notion was that dietary
interventions in early life could improve gut health and immune competence, thereby supporting
health throughout the vulnerable period post-weaning.
A relatively well studied dietary intervention in both animals and humans areβ-glucans. β-glucans
are a group of glucose polymers and are structural components of fungi, algae, bacteria, and plants.
Being the subject of numerous studies on their application in animal feed formulations, a lot is known
about the molecular mechanisms of β-glucans and their binding to specific cell receptors (e.g., Dectin-1)
along the gut lining and specific immune cells, such as antigen-presenting cells (APCs) [12,13].
As reviewed by Thompson et al., several in vitro and in vivo studies showed that β-glucans possess
immunomodulatory properties, dependent on their structure, solubility and molecular weight [14].
Especially particulate β-glucans derived from fungi (including yeast), which consist of a (1,3)-β-linked
backbone with small numbers of (1,6)-β-linked side chains, are known for their immune-stimulating
effects [15,16].
Besides the observed immunological effects, there is increasing evidence that β-glucans may
have prebiotic traits, and as such might modulate the microbiota [17]. As recently reviewed by
Atanasov et al., several fungal polysaccharides, including yeast-derived β-glucans, are already being
sold as commercial products due to their high bio-activity [18]. In the last few decades, a small
number of studies investigated the effects of yeast-derived products on the intestinal health of pigs [19].
In a recent study that used an autolyzed dried yeast cell product, no effects were shown on caecal
microbiota composition [20]. However, it should be noted that that study only investigated the effects
of a yeast-derived product in the post-weaning phase.
As outlined above, several studies have investigated the development of the gut microbiota,
and the effects of dietary fibres on porcine gut health and the immune function in the post-weaning
phase. However, only a few studies have focused their research on the immediate and early period [21].
To the best of our knowledge, no in vivo studies have investigated the effects of yeast-derived
β(1,3/1,6)-glucans (MacroGard®) on both the porcine gut microbiota and immune system in early life,
despite the promising results from several in vitro studies [22,23]. In this study, we investigated whether
early-life supplementation of yeast-derived β-glucans affects the gut microbiota as well as the immune
system. In addition, we examined the temporal dynamics of these complex systems. We hypothesized
that early life consumption of yeast-derived β-glucans alters gut microbiota development (composition)
and the immune system. Further developed and mature gut microbiota and immune system in early
life could make the animals more resilient against invasive pathogens during the weaning phase and
later in life.
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2. Materials and Methods
2.1. Ethical Statement
The animal experiment was conducted in accordance with the Dutch law on animal
experimentation and ethical requirements, which complies with the European directive 2010/63/EU
on the protection of animals used for scientific purposes. The project license application was
approved by the Dutch Central Authority for Scientific Procedures on Animals (CCD) (Permit Number:
AVD1040020173948) and the animal experiment and associated protocols were approved by the Animal
Care and Use Committee of Wageningen University and Research (Wageningen, The Netherlands).
Pigs were euthanized by intravenous injection of 20% sodium pentobarbital (Euthasol®) followed
by immediate exsanguination according to Good Veterinary Practice (GVP). All efforts were made to
minimize suffering.
2.2. Study Design
To determine the effect of β-glucans on gastro-intestinal development and the immune function
in early life, an in vivo study was performed at the Swine Research Centre (Trouw Nutrition,
Sint Anthonis, The Netherlands). The experiment was conducted with 33 sows (Hypor Libra,
Boxmeer, The Netherlands) and their litters (Maxter ×Hypor Libra sow). Sperm from a single boar
was used to inseminate all sows to reduce genetic variation in the litters. Shortly after parturition,
the piglets received an ear tag, an intramuscular iron injection, their tails were docked, and their
birth weight and sex were determined. Calcium carbonate-based powder (Power-Cal®, Power-Cal,
Sint-Oedenrode, The Netherlands) was added to all pen floors to reduce the infection pressure in
the stable. Approximately 24 h after parturition, 96 female piglets were selected and cross-fostered
to minimize possible confounding effects such as genetic background, sow parity, litter size, birth
weight and time of birth. During cross-fostering, all piglets were randomly allocated to either the
control- or treatment (β-glucan) group, while at the same time making efforts to have groups as equal
as possible in terms of body weight, sow parity, and time of birth. This resulted in six animals per pen
(experimental unit) with 16 pens in total (eight per group) which were divided over four farrowing
rooms (balanced for treatment). The complete study timeline and a schematic representation of the
experimental design are presented in Figure 1. Non-experimental (male) piglets were equally divided
over the pens, with on average six non-experimental animals per pen. All suckling piglets were kept
together with their fostering mother until weaning (approximately day 28), each sow being housed
in farrowing pens in a room with a computer-controlled climate system. Weaner diet (Table S1) was
administered three days prior to weaning (day 25–27) to allow piglets to become familiar with the
consumption of solid feed prior to weaning. At weaning, three pigs per pen (48 pigs in total) were
randomly selected and reallocated to a clean nursery facility. During the entire post-weaning period
all pens were provided with solid feed and water ad libitum. From day 28 until day 44, all pigs received
a weaner diet in combination with the feed intervention, and from day 45 until the end of the study the
piglets solely consumed a nursery diet (Table S1). Pigs with a history of medication, leg/claw problems,
or growth retardation were excluded from the selection. At day 27, 44, and 70 (dissection), sixteen
piglets were sacrificed (n = 8 per treatment group, at each time point).
Microorganisms 2020, 8, 1573 4 of 24
Microorganisms 2020, 8, x FOR PEER REVIEW 4 of 25 
 
 
Figure 1. Study timeline (A). From day 2 until day 44, all piglets orally received either β-glucans or a 
control treatment (tap water) every other day (1). A sub-selection of piglets was weaned on day 28 
(3). Pigs were vaccinated with Salmoporc®  on day 21 (primary vaccination; (2) and on day 45 (booster 
vaccination; (4). Faecal samples were collected on days 4, 8, 14, 26, 35, 43, 59 and 69 (squares; □). Blood 
samples were taken on days 14, 26, 35, 43, 59, and 69 (circles; ●). A subset of animals were sacrificed 
on days 27, 44, and 70 (cross; †). Schematic representation of the experimental design showing the 
remaining number of animals per treatment over time as determined by deselection or dissection of 
animals (B). The control and the β-glucan groups are presented as yellow and green, respectively. The 
dashed line separates the pre-weaning and post-weaning time points. 
2.3. Experimental Procedures 
2.3.1. Dietary Intervention and Oral Vaccination 
From day 2 until day 44 of the study, piglets received either β-glucans (MacroGard® ) or a control 
treatment (tap water) every other day. Piglets received the dietary interventions orally using 
disposable syringes (Discardit II, BD). MacroGard®  (Orffa Additives B.V., Werkendam, The 
Netherlands), which consisted of 100% yeast (Saccharomyces cerevisiae) cell walls, contains a minimum 
of 60% particulate β(1,3/1,6)-glucans with an approximate molecular weight of 200 kDa [24]. These 
β-glucans were not present as soluble molecules but were instead in particulate form as part of yeast 
cell wall fragments. Especially these (yeast-derived) particulate β-glucans were known for their 
immune-stimulating effects [15,16]. Other components of MacroGard®  were lipids (max. 18%), 
proteins (max. 8%) and raw ash (max 10%). In addition, the batch did not contain lipopolysaccharides 
as was assessed in a previous study [22]. The dosage of β-glucans was gradually increased every 
week with 50 mg, starting from 50 mg per administration in week one to 300 mg per administration 
in week six. These dosages of β-glucans were chosen by taking previous studies into consideration 
[25]. To investigate the effect of the yeast-derived β-glucans on the immune function, an oral live 
attenuated vaccine (Salmoporc®  STM (lot number 0270617), IDT Biologika GmbH, Dessau-Rosslau, 
Germany) was administered on day 21 (primary vaccination) and day 45 (booster vaccination). This 
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2.3. Experimental Procedures
2.3.1. Dietary Intervention and Oral Vaccination
From day 2 until day 44 of the study, piglets received either β-glucans (MacroGard®) or a control
treatment (tap water) every other day. Piglets received the dietary interventions orally using disposable
syringes (Discardit II, BD). MacroGard® (Orffa Additives B.V., Werkendam, The Netherlands),
which consisted of 100% yeast (Saccharomyces cerevisiae) cell walls, contains a minimum of 60% particulate
β(1,3/1,6)-glucans with an approximate molecular weight of 200 kDa [24]. These β-glucans were not
present as soluble molecules but were instead in particulate form as part of yeast cell wall fragments.
Especially these (yeast-derived) particulate β-glucans were known for their immune-stimulating
effects [15,16]. Other components of MacroGard® were lipids (max. 18%), proteins (max. 8%) and
raw ash (max 10%). In addition, the batch did not contain lipopolysaccharides as was assessed in a
previous study [22]. The dosage of β-glucans was gradually increased every week with 50 mg, starting
from 50 mg per administration in week one to 300 mg per administration in week six. These dosages of
β-glucans were chosen by taking previous studies into consideration [25]. To investigate the effect of
the yeast-derived β-glucans on the immune function, an oral live attenuated vaccine (Salmoporc® STM
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(lot number 0270617), IDT Biologika GmbH, Dessau-Rosslau, Germany) was administered on day
21 (primary vaccination) and day 45 (booster vaccination). This vaccine was registered for oral
application in pigs to diminish bacterial colonization, excretion, and clinical symptoms of infection
with Salmonella Typhimurium. The vaccine suspension, containing 5 × 108–5 × 109 CFU/mL of the live
attenuated Salmonella enterica serovar Typhimurium, was freshly prepared according to manufacturer’s
instructions prior to oral administration.
2.3.2. Blood and Faecal Sampling
Blood and faecal samples were collected at different time points during the study for the evaluation
of immune function and microbiota composition, respectively. Faecal samples were collected on days
4 (n = 24 per treatment group), 8 (n = 24), 14 (n = 24), 26 (n = 24), 35 (n = 16), 43 (n = 16), 59 (n = 8),
and 69 (n = 8). Rectal stimulation was performed by inserting the tip of a wetted (with sterilized H2O)
cotton swab (PurFlock Ultra, Puritan) into the rectum, by making small, gentle movements (circular
and back- and forward). These fresh faecal samples were collected in cryotubes, immediately placed
on dry ice and stored at −80 ◦C until further processing. DNA isolation from faeces was done on
all faecal samples from animals that were dissected. Blood was collected on days 14, 26, 43, and 69
from the jugular vein of the pig using Natrium Heparin tubes (S-monovette®, Sarstedt, Germany).
Blood samples were either kept at room temperature (RT) until further processing for cell analysis
or centrifuged at 2000× g for 10 min to collect serum. Serum was stored at −20 ◦C until further use.
Piglets were sampled in a random order and weighed directly before sample collection.
2.3.3. Dissection
After euthanasia and exsanguination, the ileocecal mesenteric lymph node (MLN) was removed
and stored on ice-cold (4 ◦C) RPMI 1640 Medium (with GlutaMAX™ supplement, Gibco®), containing
10% fetal calf serum (FCS, Gibco®) and 1% L-Glutamine (Gibco®). Subsequently, the GI tract
was removed from the abdominal cavity of the piglet, and the jejunum, ileum, and caecum were
identified and segmented accordingly. Digesta samples from these GI segments were taken on day
27 (pre-weaning), and day 44 and 70 (post-weaning) by gently squeezing the segment content into
a plastic container. Next, the collected digesta was completely homogenized using a clean spatula.
Approximately 1 g of homogenized digesta was stored in a sterile cryogenic vial, snap-frozen on dry
ice and stored at −80 ◦C until further processing. The remainder of the digesta from each GI segment
was mixed with H2O for pH measurement (Figure S1) using a pH meter (ProLine B210).
2.4. Measurements
2.4.1. Microbiota Analysis
DNA was extracted from faecal and digesta samples using a customized Maxwell 16 Total RNA
protocol (Promega Corp., Madison, WI, USA) with Stool and Transport and Recovery Buffer (STAR;
Roche Diagnostics Corp., Rotkreuz, Switzerland). Briefly, 50 mg of previously frozen (−80 ◦C) faeces
or 100 mg of digesta was homogenized with 0.25 g of sterilized 0.1 mm zirconia beads and three
2.5 mm glass beads in 300 µL STAR buffer for 3 × 1 min at 5.5 m s−1 using a bead beater (Precellys 24,
Bertin Technologies, Montigny-le-Bretonneux, France), with a waiting step of 15 s in between. Samples
were incubated with shaking at 300 rpm for 15 min at 95 ◦C and centrifuged for 5 min at 4 ◦C and
16,100× g. The supernatant was removed and the pellets were processed again using 200 µL fresh STAR
buffer. Samples were incubated at 95 ◦C and centrifuged as before. The supernatant was removed,
pooled with the first supernatant and 250 µL was used for purification with Maxwell 16 Tissue LEV
Total RNA Purification Kit, catalogue no. AS1220 (Promega Corp.) customized for DNA extraction
in combination with the STAR buffer. DNA was eluted with 50 µL of DNAse- and RNAse-free
water (Qiagen). DNA concentrations were measured with a NanoDrop ND-1000 spectrophotometer
(NanoDrop Technologies Inc., Wilmington, DE, USA) and adjusted to 20 ng µL−1 with DNAse- and
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RNAse-free water. PCR amplification was carried out with barcoded primers directed to the V4 region
of the bacterial and archaeal 16 S rRNA gene, namely EMP_515 F (5′-GTGYCAGCMGCCGCGGTAA),
with linker ‘GT’, and EMP_806 R (5′-GGACTACNVGGGTWTCTAAT), with linker ‘CC’. PCR reactions
were done in duplicate, each in a total volume of 50 µL and containing 20 ng of template DNA. In order
to distinguish samples between sequencing reads, each sample was amplified with a unique barcoded
primer pair (200 nM each per reaction), 1 × HF buffer (Thermo Fisher Scientific, Waltham, MA, USA),
1 µL dNTP Mix (10 mM each; Roche Diagnostics GmbH, Baden-Württemberg, Germany), 1 U Phusion
Hot Start II High Fidelity DNA Polymerase (Thermo Fisher Scientific), and 36.5 µL of DNAse- and
RNAse-free water. The amplification program included 30 s initial denaturation at 98 ◦C, followed
by 25 cycles (with the exception of jejunum digesta samples which were processed with 30 cycles
to yield sufficient amplicon fragments) of denaturation at 98 ◦C for 10 s, annealing at 56 ◦C for 10 s,
elongation at 72 ◦C for 10 s, and a final extension at 72 ◦C for 7 min. The PCR product presence and size
(≈290 bp) was confirmed with gel electrophoresis using a 1% agarose gel. In each library, 69 unique
barcode tags were used and two artificial (mock) communities were included in addition to a water
(blank) control [26]. PCR products were purified using the HighPrep PCR kit (MagBio Genomics Inc.,
Gaithersburg, MD, USA), and DNA concentrations were measured using the Qubit dsDNA BR Assay
Kit (Thermo Fisher Scientific). Of each barcoded sample, 200 ng DNA was added to an amplicon
pool that was subsequently concentrated using the HighPrep PCR kit to a volume of 20 µL. The DNA
concentration of the amplicon pool was measured using the Qubit dsDNA BR Assay Kit and the
libraries were sent for Illumina HiSeq sequencing (Eurofins Genomics, Ebersberg, Germany). Amplicon
sequence data were processed and analysed using NG-Tax 2.0 [27] and annotated using the SILVA
132 database [28].
2.4.2. Serology
To analyse the antibody response against Salmonella Typhimurium, an in-house ELISA was
optimised and performed as described previously [29]. In short, Salmoporc®, containing a live
attenuated strain of Salmonella enterica serovar Typhimurium, was streaked on a MacConkey agar
(Sigma Aldrich) plate and grown overnight at 37 ◦C. Then, a single colony was used to inoculate
2 mL of lysogeny broth (LB) medium, and grown overnight under aeration on a shaker (200 rpm) at
37 ◦C. The following day, 1 mL of the overnight culture was transferred to a 50 mL tube containing
15 mL of LB medium. The 50 mL tube was placed under aeration on a shaker (200 rpm) at 37 ◦C until
reaching the exponential growth phase (OD600 nm = 0.6–0.8). Thereafter, the bacteria were pelleted
by centrifugation at 10,000 rpm for 5 min and washed two times with cold PBS. Medium-binding
96 well plates (clear, flat bottom, Greiner Bio-One, Vilvoorde, Belgium) were coated with 100 µL of
the bacterial suspension (2 × 108 bacteria/mL) and incubated overnight at 4 ◦C. The following day,
non-attached bacteria were removed and attached bacteria were fixed with 4% paraformaldehyde
for 2 h at RT. Plates were blocked overnight at RT with a blocking solution consisting of 5% milk
powder (ELK, FrieslandCampina, Amersfoort, The Netherlands) in demi water, and stored at 4 ◦C
until usage. After blocking, plates were washed with PBS/Tween20 (0.05%) and 100µL of diluted
serum samples were added. Serum samples were diluted 250 × (IgG) and 50 × (IgA, IgM) in blocking
solution, and incubated for 1 h at RT. Plates were washed two times, and 100 µL of 50,000 times
diluted (in blocking solution) horseradish peroxidase (HRP) conjugated goat anti-Porcine IgG, IgM
or IgA (Novus Biologicals, Centennial, CO, USA) was added. After 30 min, plates were washed five
times and incubated with 100 µL of 3,3′,5,5′-tetramethylbenzidine (TMB) substrate solution (Enhanced
K-Blue®, Neogen, Lansing, MI, USA). After 15 min the reaction was stopped with 100 µL of a 2% HCl
stop solution, and the optical density (OD) of the plates was measured at a wavelength of 450 nm
(Multi-Mode Microplate Reader FilterMax F5).
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2.4.3. Cell Isolation
Collected blood was diluted 1:1 with PBS (containing 0.5 mM EDTA) within 4 h of collection
and transferred to Leucosep® tubes using a 60% FICOLL-PAQUE™ Plus density-gradient to isolate
the peripheral blood mononuclear cells (PBMCs). Remaining red blood cells were lysed with ACK
lysis buffer (Gibco®). MLN cells were collected by cutting the nodules in smaller pieces, and gently
squeezing and flushing the cells through a sterile Falcon® cell strainer (100 µm, Corning®, New York,
NY, USA), using a syringe plunger and sterile Mg2+ and Ca2+ free PBS (Lonza, Basel, Switzerland).
Both isolated PBMCs and MLN cells rested overnight at 4 ◦C until further processing.
2.4.4. Stimulation Assay
After resting overnight, 1 × 106/well of PBMCs and MLN cells were separately transferred
to a 96 well clear round bottom plate (Greiner Bio-One). Plates containing wells with LPS
(serotype O55:B5/L2880, Sigma-Aldrich, St. Louis, MO, USA), with Concanavalin A (Con-A, C2010,
Sigma-Aldrich), or without a stimulus (cell culture medium only) were prepared the previous day and
stored at 4 ◦C overnight. The next day, the plates were placed at 37 ◦C for 30 min before addition of the
cells. Cells were incubated with 0.1, 1 or 10 µg/mL of LPS, with 5, 2.5, or 1.25 µg/mL or without stimuli
for 24 h at 37 ◦C (5% CO2). After 24 h of incubation, the plates were centrifuged at 300× g for 3 min to
spin the cells down. Subsequently, the cell culture supernatant was collected and immediately stored in
96 well polypropylene plates (Nunc®, MicroWellTM, Sigma-Aldrich) at −80 ◦C until further processing.
2.4.5. Flow Cytometry
Isolated PBMCs and MLN cells were stained with a DC or T lymphocyte/NK cell antibody panel
(Table 1). To analyse these cells, 5 × 106 (DC panel) or 1 × 106 (T lymphocyte/NK) freshly isolated
PBMCs or MLN cells (per animal) were placed in a 96 well polypropylene plate (Nunc®, MicroWellTM,
Sigma-Aldrich). Per well, 200 µl FACS buffer (Mg2+ and Ca2+ free PBS; Lonza), 2 mM EDTA (Merck,
Kenilworth, NJ, USA), 0.5% BSA fraction V (Roche, Basel, Switzerland) was added and the plates
were centrifuged at 400× g for 3 min at 4 ◦C to wash the cells. After washing, extracellular cell
surface markers (Table 1) were stained with antibodies for 30 min on ice (in the dark), followed by
three washing steps with cold PBS. Subsequently, cells were stained with (in PBS diluted) Fixable
viability dye eFluorTM 506 (eBioscienceTM) and Streptavidin-BV421 (DC panel) for 30 min, followed by
a washing step with FACS buffer. Then, 100 µL Fix/Perm buffer (eBioscienceTM) was added to each
well and incubated for 45 min at RT, to allow for intracellular staining. After incubation, cells were
washed three times in Perm buffer (eBioscienceTM), followed by the incubation with the intracellular
antibody mix (Table 1) in 35 µL Perm buffer for 30 min at 4 ◦C. After two other washing steps with
Perm buffer, cells were resuspended in 200 µL FACS buffer and measured for 150 s (NK cells/T cells)
or 300 s (DCs) on the FACS CANTO II at a medium flow rate. Beads were used for single stained
controls using compensation beads (UltraComp eBeadsTM, ThermoFisher), and cells were used for
Fluorescence Minus One (FMO) controls to control for spectral overlap. Flow cytometry data analysis
was performed by using FlowJoTM software (Version 10). Gating of DC subsets, NK cells and T cell
subsets was performed in line with previous studies [30–32]. Examples of the gating strategies can be
found in Figure S2 (DCs) and Figure S3 (T lymphocytes and NK cells).
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Table 1. Antibodies used to identify DC subsets, NK cells and T cell subsets in PBMCs and mesenteric
lymph node (MLN) cells.
Antibody Host/Isotype Clone Fluorochrome Company Dilution
CD14 Mouse, IgG2b MIL-2 FITC Bio-Rad 1:50
CD172a Mouse, IgG2b 74-22-15A PE BD Biosciences 1:40
CD4a Mouse, IgG2b 74-12-4 PerCP-Cy5.5 BD PharmingenTM 1:320
CADM1 Chicken, IgY 3E1 Biotin MBL 1:200
Streptav. n/a n/a BV421 BD HorizonTM 1:50
CD152 * Mouse, IgG2a n/a APC Ancell 1:320
CD3ε Mouse, IgG2a BB23-8E6-8C8 PE-CyTM7 BD PharmingenTM 1:160
CD4a Mouse, IgG2b 74-12-4 PerCP-Cy5.5 BD PharmingenTM 1:320
CD8a Mouse, IgG2a 76-2-11 FITC BD PharmingenTM 1:10
FoxP3 Rat, IgG2a FJK-16s Alexa Fluor® 700 ** eBioscienceTM 1:20
Ki67 Mouse, IgG1 B56 BV421 ** BD HorizonTM 1:80
CD25 Mouse, IgG1 K231.3B2 Purified *** Bio-Rad 1:200
γδ T cells Rat, IgG2a MAC320 PE BD PharmingenTM 1:20
*; Human CD152 (CTLA-4) murine Ig fusion protein was used to detect CD80 and CD86 on DC subsets. **; Antibodies
against intracellular antigens. ***; The antibody CD25 (purified) was labelled with the ReadiLink™ Rapid iFluor™
647 Antibody Labeling Kit (Aat Bioquest, Sunnyvale, CA, USA).
2.5. Statistical Analysis
All R-scripts, data files and pdf files with extensive information on the performed analyses can be
accessed through the following DOI: 10.4121/12999620. Alternatively, these files can be found under
the following Github page: https://github.com/mibwurrepo/de-Vries-et-al-2020-porcine-study-beta-
glucans.
2.5.1. Microbiota Analysis
In order to estimate the impact of yeast-derived β-glucans on alpha diversity of the microbiota
in piglets’ faeces and digesta, Shannon and InvSimpson diversities were calculated for each sample.
Shannon and InvSimpson diversities were both chosen as Shannon’s diversity index gives more weight
to rare species and Simpson’s index gives more weight to common species. It should be noted that
really rare sequences are missing from the dataset as NG-Tax 2.0 uses an abundance threshold of 0.1%
for amplicon sequence variants (ASVs) in a given sample. Shannon and InvSimpson diversities were
used in a Linear Mixed-Effects Model (i.e., Shannon~Day_of_study * Treatment) to test for significant
differences between time points and treatment groups (nlme package v3.1-140) [33]. To estimate the
impact of β-glucans on overall microbiota composition, PERMANOVA tests were performed using
Bray-Curtis dissimilarities at ASV level (9999 permutations). The homogeneity assumption was tested
by calculating Bray-Curtis dispersion for each group followed by ANOVA tests. To visualize the beta
diversity in faecal samples over time, a Principal Coordinates Analysis (PCoA) plot was generated using
weighted Unifrac dissimilarities. In order to estimate the impact of β-glucans as a dietary intervention
on the relative abundance of specific genera in piglet faeces, reads of the ASVs were first aggregated to
genus level using the tax_glom function of the phyloseq R package [34], after which read frequencies
were transformed to compositional data using the transform function of the microbiome R package [35].
Genera were filtered to exclusively include genera that had a relative abundance of 0.1% in at least 50%
of the samples. Resulting genera were tested for differential relative abundance using the Generalized
Additive Models for Location, Scale and Shape (GAMLSS) with a zero-inflated beta family (function
taxa.compare) with GAMLSS-BEZI as a statistical method in the metamicrobiomeR package [36].
Dietary intervention was used as the main variable for comparison and day of study and department
(farrowing rooms) were used as adjusting variables. Ear tag was indicated as the identifier to enable a
longitudinal approach and “fdr” (False Discovery Rate) was chosen as the method for multiple testing
adjustment (p.adjust < 0.05 as the threshold). This analysis was performed on three different datasets:
a dataset containing only pre-weaning faecal samples, one with only post-weaning faecal samples and
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one dataset containing faecal samples from all time points (both pre- and post-weaning). To get a better
overview of the genera that mostly contributed to the differences in microbiota composition between
the treatment groups over time, weighted Unifrac distance-based Principal Response Curve (dbPRC
using package Vegan [37,38]) analysis was performed. For these dbPRC figures, pre- and post-weaning
datasets were used to investigate these distinct periods in the piglet’s microbiota development.
2.5.2. Immunological Analysis
To assess if yeast-derived β-glucans alters the immune system, a Student’s t-test (unpaired) was
performed using R statistical software (version 3.6.2). Additionally, a Two-way ANOVA followed by a
Tukey post-hoc test was performed to assess the effects over time and the interaction between time and
treatment. Normality of data (Shapiro-Wilk test) and homogeneity of variances (Levene’s test) were
checked prior to statistical testing. Skewness values between −2 to +2 were considered acceptable [39].
Extreme outliers (indicated by R) were removed from the analysis. When the statistical assumptions
were not met, data were log transformed. Data are presented as untransformed means ± SEM. Results
with an adjusted p-value below 0.05 (p < 0.05) were considered statistically significant and results
between 0.05 and 0.1 (0.05 < p < 0.10) were considered a trend. Significant results were tested for
confounding factors, including body weight at birth, using an ANCOVA.
2.5.3. Correlation Analysis
To assess possible correlations between microbial composition, study factor- and immunological
data, first microbiota ASVs were aggregated at the genus level and transformed to compositional
abundances. Then, a prevalence filter was applied with a 0.1% abundance threshold in at least 50% of
the samples. Resulting genera were combined with study factor data and immunological data and
a test for association was performed for each parameter pair, using a Pearson moment correlation




To assess potential differences in microbiota composition between β-glucan treated animals and
control animals, both faecal and luminal samples were collected at multiple time points (Figure 1).
No significant differences for alpha diversity were observed between the treatment groups when
including all faecal time points (Figure 2; p = 0.11 for Shannon, p = 0.60 for InvSimpson). However,
when including exclusively pre-weaning faecal time points, a significant difference in alpha diversity
between the treatment groups was observed for the Shannon diversity (p < 0.04 for Shannon, p < 0.10
for InvSimpson). The significant difference for Shannon’s diversity indicates that low abundance ASVs
are mostly contributing to the differences in alpha diversity. As expected, piglet faecal and luminal
microbiota composition showed different temporal trends in alpha diversity, with alpha diversity
in faeces increasing up to day 35 before reaching a plateau that lasted until the end of the study.
Furthermore, digesta from different gut segments all showed a similar pattern with a higher α-diversity
on day 27 in comparison to day 44 (p < 0.001).
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(d4-70) a d by faeces (fcs) or gut segment; jejunum (jej), ileum (ile), caecum ( ). Letters (a, b, c) represent
significant differences (p < 0.05) between time points. The horizontal line with the corresponding
asterisk represents the significant difference between treatment groups in the pre-weaning period,
calculated using a Linear Mixed-Effects Model (*; p < 0.05).
3.1.2. Microbiota Composition over Time
The dynamic shifts in the microbiota composition in the faeces and digesta over time were
examined at the phylum and family classification level. At the phylum level (Figure 3A), the microbiota
composition in faeces transitioned from a Firmicutes, Bacteroidetes, Proteobacteria, and Fusobacteria
predominated community on day 4 to a Firmicutes and Bacteroidetes predominated community at later
time points. Both the jejunum and ileum digesta were characterized by a Firmicutes predominated
community a all time poin s (day 27, 44, n 70), wherea the cae al microbiota was found to be
predominated by Firmicutes and Bacteroidetes at all time poin s. Furthermore, the av rage relative
abundance of the Euryarchaeota i faeces (Figure S5) increased over time during the pre-weaning period
from below 0.03% on day 4 to reach an average relative abundance of over 6% on day 26. Post-weaning
faecal samples show a more stable pattern of the Euryarchaeota with a relative abundance of 1–2% on
each time point until day 69. Interestingly the Euryarchaeota were present in caecal digesta with a similar
abundance (1.5%) on day 27, while at later time points the mean relative abundance in caecal digesta
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was drastically lower (<0.1% at both day 44 and day 70). In jejunum and ileum digesta, the relative
abundance of the Euryarchaeota was very low at all time points, except for jejunum digesta on day 70
(Figure S5). At the family level (Figure 3B), a dramatic shift of taxa could be observed in faeces over
time, with large shifts occurring from day 4 to day 8 and during the weaning transition, from day
26 to day 35. Jejunum digesta was predominated by Lactobacillaceae at all time points, while ileum
digesta was predominated by Lactobacillaceae at day 27 and day 44 followed by Clostridiaceae_1 on day
70. Caecum digesta was predominated by Lactobacillaceae, Ruminococcaceae, and Prevotellaceae on day
27, by Lactobacillaceae and Prevotellaceae on day 44 and by Prevotellaceae on day 70. For a more detailed
overview of the relative abundance of several families in faecal samples over time, see Figure S6.
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Figure 3. Taxonomic composition of the piglet faeces and digesta over time at phylum (A) and family
(B) level. Data are given as the mean relative abundance by sampling time point (d4-70) and by faeces
(fcs) or gut segment; jejunum (jej), ileum (ile), caecum (cae). Data includes samples from both treatment
groups and shows the 25 most abundant families and 10 most abundant phyla.
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3.1.3. Beta Diversity
Beta diversity was calculated at the ASV level using Bray-Curtis dissimilarities and a PERMANOVA
test was performed on all faecal samples with treatment and time point as model parameters.
The effect of treatment was not significant (p > 0.14), but a strong time effect was observed (p < 0.001).
When including only pre-weaning faecal samples, however, the effect of treatment was significant
(p < 0.042), but the contribution of treatment to the variance was low (R2 < 0.0031). This was not
observed when only post-weaning samples were included. Bray-Curtis dispersions of pre- and
post-weaning faecal samples were compared and showed to be significantly different (ANOVA,
p < 0.001), with dispersion being lower in post-weaning faecal samples. Principal Coordinates Analysis
(PCoA) based on weighted Unifrac distance of the piglet faecal microbiota revealed significant temporal
shifts and a distinct separation between pre- and post-weaning faecal samples (Figure 4). The wide
distribution of the samples collected on days 4, 8, and 14 reinforced the notion that the overall
microbiota composition of piglet faeces changes dramatically in the first two weeks after birth.
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3.1.4. Differentially Abundant Genera between Treatment Groups
When comparing the relative abundances of individual taxa in pre-weaning faecal samples at
the genus level, three out of a total of 31 genera that passed the prevalence filter were found to be
differentially abundant between the β-glucan and control group (Figure 5). Especially on days 8
and 14, the genus Methanobrevibacter was less abundant in animals that received β-glucans, while the
genera Fusobacterium and Ruminococcaceae_UCG-002 were more abundant at a number of time points
in animals that received β-glucans. No differentially abundant genera were found in faecal samples of
the post-weaning period, nor were differentially abundant genera found when all faecal samples were
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used in the GAMLSS model. The dbPRC analysis (Figure S4) revealed several additional genera that
contributed to the changes between treatment groups over time.
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Figure 5. Relative abundances (by fraction) of differentially abundant genera in faeces during the
pre-weaning period (d4-26). Shown genera resulted from comparing β-glucan animals to control
animals using a GAMLSS model. Dietary intervention was used as the main variable for comparison
and day of study and department were used as adjusting variables. Ear tag was used as an identifier
and “fdr” was chosen as the method for multiple testing adjustment (p.adjust < 0.05).
3.2. Immunological Analysis
3.2.1. Immunological Response to Oral Vaccination
To analyse if supplementation of β-glucans in early life induces changes to the host’s innate and
adaptive immune system, differe t types of analysis wer performed to a sess this on a local
systemic level. I this study, an oral vaccination gainst Salmonella Typhimurium was administered to
measure wh ther yeast-derived β-gluc ns h ve an effect on the r sponsiveness of the immune system.
As expected, a clear and ignificant increase of Salmo ella-specific IgM and IgA antibodies could b
ob erved aft r both the primary and the seconda y (bo ster) vaccination (Figure 6A,B). An increase in
antigen-specific IgG anti dies was onl observ d after the sec nd vaccination (Figure 6C). Despite
the clear crease of antibody titres, no alt red antibody response to the Salm ella va cine strain was
observ d b tween the β-glucan and control group during the pre- and post-weaning phase of the
study (Figure 6A–D).
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β-glucan treated animals showed an increased IL-10 production on day 27 (Figure 7C), albeit not 
significant (p = 0.09; T-test). No differences in IL-10 production were observed for stimulated PBMCs 
(Figure S8). Interestingly, MLN cells from β-glucan treated animals also produced more IL-10 when 
left unstimulated (medium only) compared to unstimulated MLN cells from the control animals (p = 
0.057; T-test). No such differences were observed for the post-weaning time points (day 44 and 70, 
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differences in TNFα production by MLN cells were observed between the treatment groups (Figure 
S8), but stimulation of PBMCs obtained at day 27 from β-glucan treated animals showed a decreased 
TNFα production upon stimulation with Con-A (p = 0.024; T-test) and LPS (not significant) (Figure 
7B,D). Furthermore, IL-10 production changed over time as observed for Con-A stimulated MLN 
cells (Figure 7C), independent of the different treatment groups. As for LPS stimulated PBMCs 
(Figure 7C), a significant increase of TNFα was only observed for β-glucan treated animals (time-
treatment interaction).  
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of cine (Salmoporc®) administration (d21 and d45). From every pen, two c ntrol nimals (circles;
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and f llowed over time (n = 16 per reatment group). Every symbol r presents a single observation.
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3.2.2. Ex Vivo Stimulation of MLN Cells a
Figure 7 shows the production of the fl atory cytokine IL-10 by MLN cells and the
production of the pro-inflam atory cytokine TNFα by PB s, it S or on-A.
The cytokines were measured at three differ nt tim points (one pre- and two post- eaning) duri the
study. Significant differences were only observed pre-weaning. On day 27, MLN cells from β-glucan
treated animals produced higher levels of IL-10 upon stimulation with 10 µg/mL LPS (p = 0.008;
T-test) in comparison to LPS stimulated MLN cells from non-treated animals (Figure 7A). Using
a lower concentration of LPS (1 µg/mL) showed the same pattern but resulted in a lower level of
IL-10 production (Figure S7). In accordance with these results, Con-A stimulated MLN cells from
β-glucan treated animals showed an increased IL-10 production on day 27 (Figure 7C), albeit not
significant (p = 0.09; T-test). No differences in IL-10 production were observed for stimulated PBMCs
(Figure S8). Interestingly, MLN cells from β-glucan treated animals also produced more IL-10 when
left unstimulated (medium only) compared to unstimulated MLN cells from the control animals
(p = 0.057; T-test). No such differences were observed for the post-weaning time points (day 44
and 70, respectively) and the variation between individual animals increased in the post-weaning
phase. No differences in TNFα production by MLN cells were observed between the treatment
groups (Figure S8), but sti ulation of PBMCs obtained at day 27 from β-glucan treated animals
showed a decreased TNFα production upon stimulation with Con-A (p = 0.024; T-test) and LPS (not
significant) (Figure 7B,D). Furthermore, IL-10 productio changed over time as observ for Con-A
stimulat d MLN cells (Figure 7C), independent of the differ nt treatment groups. As for LPS stimulated
PBMCs (Figur 7C), a significant increase of TNFαwas only observed for β-glucan treated animals
(time-treatment interaction).
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decreased percentage of proliferating NK cells (p = 0.009; T-test, p = 0.010; Two-way ANOVA) and γδ 
T cells (p = 0.049; T-test, p = 0.034; Two-way ANOVA) was observed for β-glucan treated animals on 
day 26 (Figure 8A,D). As for MLN cells, the same immune cell populations were analysed, with the 
exception of NK cells. On day 44, a higher percentage of cDC1 (p = 0.011; T-test) and cytotoxic (CTL) 
cells (p = 0.035; T-test) was observed in β-glucan treated animals. In contrast, a lower expression of 
the cell maturation marker CD80/86 was observed for pDCs on day 27 (p = 0.024; T-test) and 70 (p = 
0.034; T-test). Interestingly, correlation analysis showed that the Romboutsia genus positively 
correlates with the expression of the cell maturation marker CD80/86 on cDC1 cells (Figure S9). 
Furthermore, a significant time effect was observed for almost all analysed cell populations (Tables 2 
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Figure 7. Levels of cytokines IL-10 ( ,C) and T Fα (B,D) from stimulated MLN cells and PBMCs.
MLN cells and PBMCs were sti ulate ith 10 g/ L LPS (A,B) or 5 µg/mL Con-A (C,D), or left
unstimulated (cell cult re medium only) for 24 h. Significant differences betwe n the treatm nt groups
are indicated by asterisks (**; p < 0.01 and *; p < 0.05). Letters (a, b) represent significant differe ces
(p < 0.05) b tween time points. Every dot represents a single animal from a different pen (n = 7 or 8 per
treatment group) and rror bars represent st ndard d via ions. Statistical analys w s performed for
every time point (T-test) and over tim (Two-way ANOVA). Dat were checked for normal distribution
and equal variances and log-transform d when required.
3.2.3. Analysis of Im une Cells in Bloo a t e
Cell analyse of PBMCs and ML cell t investigate the potential effects of β-glucans
on the abundance (percentage of cel s) or f t ration or proliferation) of diff rent i mune
cell po ulations, including DCs, NK cell l : PBMC, Table 3: MLN). No significant
differences were observ d for the DC subsets in PBMCs at any of the time points. However, a decreased
percentage of proliferating NK cells (p = 0.009; T-test, p = 0.010; Two-way ANOVA) and γδ T cells
(p = 0.049; T-test, p = 0.034; Two-way ANOV ) was observed for β-glucan treated animals on day 26
(Figure 8A,D). As for MLN cells, the same immune cell populations were analysed, with the exception
of NK cells. On day 44, a higher percentage of cDC1 (p = 0.011; T-test) and cytotoxic (CTL) cells
(p = 0.035; T-test) was observed in β-glucan treated animals. In contrast, a lower expression of the cell
maturation marker CD80/86 was observed for pDCs on day 27 (p = 0.024; T-test) and 70 (p = 0.034;
T-test). Interestingly, correlation analysis showed that the Romboutsia genus positively correlates
with the expression of the cell maturation marker CD80/86 on cDC1 cells (Figure S9). Furthermore,
a significant time effect was observed for almost all analysed cell populations (Tables 2 and 3), generally
with clear differences between day 14 and day 26 (pre-weaning) and between the pre- and post-weaning
time points.
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Table 2. Cell analysis of DCs, NK cells and T cells in PBMCs between treatment groups over time.
Unpaired T-Test Two-Way ANOVA
Subset Phenotype
D14 D26 D43 D69
p-value [CI] p-value [CI] p-value [CI] p-value [CI]
pDCs (%) CD14−CD4+CD172 a+CADM1− ns ns ns 0.060 ↓ [−0.66 to 34.14] T (<0.001), I (0.020)
pDCs (mat.) CD14−CD4+CD172 a+CADM1−CTLA4-Ig+ ns ns ns ns T (<0.001)
cDC1 (%) CD14−CD4−CD172 alowCADM1+ ns ns ns ns T (<0.001)
cDC1 (mat.) CD14−CD4−CD172 alowCADM1+ CTLA4-Ig+ ns ns ns ns T (<0.001)
cDC2 (%) CD14−CD4−CD172 a+CADM1+ ns ns ns ns T (0.092)
cDC2 (mat.) CD14−CD4−CD172 a+CADM1+ CTLA4-Ig+ ns ns ns ns T (<0.001)
NK cells (%) CD3−CD8α+ ns 0.060 ↓ [−0.41 to 15.68] ns ns G (0.080), T (0.063)
NK cells (act.) CD3−CD8α+CD25+ ns ns ns ns T (<0.001)
NK cells (Ki67%) CD3−CD8α+Ki67+ ns 0.009 ↓ [5.15 to 28.53] ns ns G (0.010), T (<0.001)
γδ T cells (%) CD3+TCR-γδ+ ns ns ns ns T (0.005)
γδ T cells (Ki67%) CD3+TCR-γδ+Ki67+ ns 0.049 ↓ [0.02 to 12.75] ns ns G (0.034), T (<0.001)
CTLs (%) CD3+TCR-γδ−CD8α+ ns 0.090 ↓ [−0.53 to 6.13] ns ns G (0.008), T (<0.001)
CTLs (Ki67%) CD3+TCR-γδ−CD8α+Ki67+ ns ns ns ns T (<0.001)
T helper (%) CD3+TCR-γδ−CD4+ ns ns ns ns T (<0.001)
T helper (Ki67%) CD3+TCR-γδ−CD4+Ki67+ ns ns ns ns T (<0.001)
Mem./Act. (%) CD3+TCR-γδ−CD4+CD8α+ ns ns ns ns T (<0.001)
Mem./Act.
(Ki67%) CD3
+TCR-γδ−CD4+CD8α+ki67+ ns ns ns ns T (<0.001)
Tregs (%) CD3+TCR-γδ−CD4+CD25 highFoxp3+ ns ns ns ns T (0.003)
Tregs (Ki67%) CD3+ TCR-γδ−CD4+CD25 highFoxp3+Ki67+ ns ns ns ns T (<0.001)
Ns; not significant, 0.05 < p < 0.1; trend, p < 0.05; significant. An unpaired Student’s T-test and a Two-way ANOVA were conducted to analyse the group effect per time point, and the
effects over time, respectively. G; group effect, T; time effect, I; group-time interaction, act.; activation, mat.; maturation, Mem./Act.; Memory/Activated T cells. Arrows indicate if the values
(e.g., percentage of cells) in the treatment group (β-glucan, n = 7 or 8) is significantly lower (↓) than the control group (n = 7 or 8). The 95% confidence intervals (CI) on the difference
between the means are shown for all significant results or results which show a trend.
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Table 3. Cell analysis of DCs, NK cells and T cells in MLN cells between treatment groups over time.
Unpaired T-Test Two-Way ANOVA
Subset Phenotype
D27 D44 D70
p-value [CI] p-value [CI] p-value [CI]
pDCs (%) CD14−CD4+CD172 a+CADM1− ns ns ns T (<0.001)
pDCs (mat.) CD14−CD4+CD172 a+CADM1−CTLA4-Ig+ 0.034 [3.21 to 67.89] ↓ ns 0.024 [7.75 to 92.70] ↓ G (0.007), T (0.001), I (0.08)
cDC1 (%) CD14−CD4−CD172 alowCADM1+ ns 0.011 [−0.11 to −0.02] ↑ ns T (<0.001), I (0.028)
cDC1 (mat.) CD14−CD4−CD172 alowCADM1+CTLA4-Ig+ ns ns ns T (<0.001)
cDC2 (%) CD14−CD4−CD172 a+CADM1+ ns ns ns T (0.001)
cDC2 (mat.) CD14−CD4−CD172 a+CADM1+CTLA4-Ig+ 0.084 [−62.71 to 4.50] ↑ ns ns ns
NK cells (%) CD3−CD8 a+ n/a n/a n/a n/a
NK cells (act.) CD3−CD8α+CD25+ n/a n/a n/a n/a
NK cells (Ki67%) CD3−CD8α+Ki67+ n/a n/a n/a n/a
γδ T cells (%) CD3+TCR-γδ+ ns ns ns T (<0.001)
γδ T cells (Ki67%) CD3+TCR-γδ+Ki67+ 0.089 [−15.45 to 1.26] ↑ ns ns T (<0.001), I (0.086)
CTLs (%) CD3+TCR-γδ−CD8α+ ns 0.035 [−13.03 to −0.60] ↑ ns T (0.076)
CTLs (Ki67%) CD3+TCR-γδ−CD8α+Ki67+ ns ns ns T (<0.001)
T helper (%) CD3+TCR-γδ−CD4+ ns ns ns T (<0.001)
T helper (Ki67%) CD3+TCR-γδ−CD4+Ki67+ 0.079 [−12.53 to 0.77] ↑ ns ns T (<0.001), I (0.019)
Mem./Act. (%) CD3+CD4+CD8α+ ns ns ns T (<0.001)
CD3+CD4 highCD8αlow ns ns ns T (0.002)
CD3+CD4 high CD8αlowki67+ ns ns ns T (<0.001)
CD3+CD4 lowCD8αhigh ns ns ns ns
CD3+CD4 low CD8αhighki67+ ns ns ns T (<0.001)
Tregs (%) CD3+TCR-γδ−CD4+CD25 highFoxp3+ ns ns ns T (<0.001)
Tregs (Ki67%) CD3+ TCR-γδ−CD4+CD25 highFoxp3+Ki67+ n/a n/a n/a n/a
Ns; not significant, 0.05 < p < 0.1; trend, p < 0.05; significant. An unpaired Student’s T-test and a Two-way ANOVA were conducted to analyse the group effect per time point, and the
effects over time, respectively. G; group effect, T; time effect, I; group-time interaction, act.; activation, mat.; maturation, Mem./Act.; Memory/Activated T cells. Arrows indicate if the values
(e.g., percentage of cells) in the treatment group (β-glucan, n = 7 or 8) are significantly higher (↑) or lower (↓) than the control group (n = 7 or 8). The 95% confidence intervals (CI) on the
difference between the means are shown for all significant results or results which show a trend.
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Figure 8. Cell analysis of different immune cell populations from PBMCs (A–C) and MLN cells (D–F).
Significant differences between treatments are indicated by asterisks (**; p < 0.01 and *; p < 0.05).
Letters (a, b, c) represent significant differences (p < 0.05) between time points. Data were presented as
the percentage of proliferating cells (Ki67%; A,B), percentage of cells (%; C,D,F), or mean fluorescent
intensity (MFI; E). Every dot represents a single animal from a different pen (n = 7 or 8 per treatment
group) and error bars represent standard deviations. Statistical analysis was performed for every time
point (T-test) and over time (Two-way ANOVA). All data were checked for normal distribution and
equal variances and log-transformed when required.
4. Discussion
The microbiota plays an important role in in the development of the innate and adaptive immune
system [40]. However, the interplay between diet, the gut microbiota, and the immune system is still
poorly understood, especially in early life. In this study, we investigated the impact of yeast-derived
β-glucans on the porcine gut microbiota and the immune system from birth to six weeks post-weaning.
We hypothesized that early-life supplementation of yeast-derived β-glucans (MacroGard®) alters gut
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microbial development and potentiates immunological responses in pigs. Overall, supplementation
of yeast-derived β-glucans had no profound effect on the development of the gut microbiota and
the immune system, and any observed differences were modest. However, clear time effects were
observed in the gut microbiota and the immune system between the pre- and post-weaning time points,
which gives valuable information regarding the development of these complex systems. Importantly,
no adverse effects of orally administered β-glucans were observed, and there were no indications that
β-glucans had a negative effect on physiological parameters (e.g., body weight and pH), gut microbiota,
or the immune system in early life.
Yeast-derived β-glucans are being used as functional ingredients in pig nutrition to boost gut
health. Although β-glucans have been shown to impact the immune system by binding to specific
host receptors, β-glucans can also be considered as dietary fibres. Dietary fibres can potentially be
used to impact gut microbiota composition by stimulating the growth of saccharolytic or fibrolytic
microorganisms [41]. Similarly, β-glucans may, depending on solubility, escape digestibility in the
upper GI tract and may arrive in the lower GI tract where they are broken down by saccharolytic
bacteria into short-chain fatty acids (SCFAs) [42]. A meta-analysis on the impact of the inclusion of
cereal-derived β-glucans in feed has indeed shown a positive correlation with the presence of the
SCFA butyrate in the colon [43]. In the present study, three genera were found to be differentially
abundant over time in faeces during the pre-weaning phase when given yeast-derived β-glucans as
dietary intervention, including Methanobrevibacter, Fusobacterium, and a genus within the family of
Ruminococcaceae. Interestingly, in a porcine study in which dietary fibres were administered during
the pre-weaning period (day 14 until weaning), effects were seen on the relative abundance of several
genera in the mid-colon, amongst which two genera in the Ruminococcaceae family [44], highlighting
the potential of microbiota modulation by dietary fibres. In a study where the effects of three purified
β-glucans were tested on members of the GI tract, all three were shown to reduce the Enterobacteriaceae
population [45]. In the current study, this shift in Enterobacteriaceae was, however, not observed.
Besides the differentially abundant genera, minor but significant differences in alpha and beta
diversity were found in faeces between treatment groups in the pre-weaning period. These differences
were not found in digesta from jejunum, ileum or caecum, which might be explained by the
smaller sample size. As expected, a clear temporal pattern was observed for both treatment groups.
This includes a clear separation between pre- and post-weaning time points as demonstrated before
in similar studies [46–48]. The alpha diversity increased in the early pre-weaning phase (day 4) up
to the first post-weaning time point (day 35), after which a plateau was reached. This is in line with
previous studies [46,47]. In another study, alpha diversity reached a plateau from day 24 onwards [21].
This outcome likely has to do with the earlier time of weaning (day 21), demonstrating the dominant role
that the weaning transition has on gut microbiota maturation. The GI tract’s microbiota composition
found in the present study is comparable to that observed in other studies in terms of main phyla in
faeces and caecum, both pre- and post-weaning [49–51]. In addition, main phyla found in the jejunum
and ileum post-weaning were comparable to the results from another study [52]. In addition, a study
by Kim et al. found that the Prevotellaceae family is predominant at ten weeks of age [50], which was
also observed in our study. Moreover, the temporal pattern of the composition and relative abundance
of archaeal taxa is comparable with data from multiple studies [49,53].
Both the composition and development of the microbiota as well as the innate and adaptive
immune maturation are influenced by exposure to commensal microorganisms and dietary antigens [4].
Dietary β-glucans are recognized by pathogen recognition receptors, the most important one being
Dectin-1 [54]. Sonck et al. demonstrated that Dectin-1 is expressed in the spleen, MLN, lungs, and along
the digestive tract of pigs [55]. Immune cells, including DCs, are also known to express Dectin-1 in
human and mice, but this has not yet been shown for porcine immune cells [56,57]. Recognition of
β-glucans by immune cells may induce altered immune responses upon a secondary stimulation,
thereby influencing the immune competence of the pig. To test this, we assessed if pigs treated with
β-glucan showed an enhanced immune response to a live attenuated Salmonella vaccine (Salmoporc®).
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A clear vaccine-induced increase in Salmonella specific antibodies was observed, but no differences
were found between the control and β-glucan group. This could imply that the vaccination induced an
immunological response that was too strong to determine the subtle effects of this dietary intervention
on the systemic immune competence, or that yeast-derived β-glucans do not enhance the systemic
immune system. In line with these results, we did not see major differences in the percentage and
proliferation of T-cell subsets in both blood and the MLN. These results are in accordance with a
previous study that investigated the effect of (purified) yeast-derived (1,3/1,6)-β-d-Glucan (Wellmune
WGP®) on the vaccination response and T-cell subsets in neonatal piglets. The authors did not find
any effect of this dietary supplement on intestinal or immune development and it did not improve the
antibody response to vaccination in neonatal piglets [58].
Interestingly, when we stimulated PBMCs from β-glucan treated animals ex vivo with LPS
or Con-A, we observed a reduction in the production of the pro-inflammatory cytokine TNFα on
day 26. In line with these findings, ex vivo stimulated MLN cells from β-glucan treated animals
produced higher levels of the anti-inflammatory cytokine IL-10 on day 27. These results suggest that
yeast-derived β-glucans induce a more anti-inflammatory or tolerant state of the systemic immune
system. This is also suggested by the reduced percentages of CTLs and proliferating NK cells and γδ T
cells in PBMCs from β-glucan treated animals on day 26. The observed reduction of TNFα in β-glucan
treated animals has been observed in other porcine in vivo studies. Vetvicka et al. showed a significant
reduction of TNFα in blood serum after an endotoxin challenge with LPS [59]. In addition, Li et al.
observed a decrease of TNFα production by blood lymphocytes from β-glucan treated pigs which
were stimulated ex vivo with LPS [60]. Taken together, these findings suggest that β-glucans may alter
immune cell responses upon a secondary stimulus as was observed in a study by dos Santos et al. [61],
in which they showed a significant increase in IL-10 production after 2 and 4 h of infection with
L. braziliensis in β-glucan trained macrophages. The modest effects of yeast-derived β-glucans on the
immune system were primarily observed in the pre-weaning phase, which is in line with the findings
from the microbiota analysis (Figures 2 and 3). A more complex diet after weaning may impair the
ability to identify any subtle changes induced by yeast-derived β-glucans in the post-weaning period.
Most studies suggest that yeast-derived β-glucans improve the overall health of pigs. However,
strong and consistent evidence is lacking, and no studies have investigated its impact on both the gut
microbiota and the immune system. The present study shows that yeast-derived β-glucans primarily
induce effects in the gut microbiota and immune system early in life. During the pre-weaning period,
the diversity of the faecal microbiota was lower in animals that received β-glucans. This is unexpected,
as fibrous components typically result in increased microbial diversity [62]. As previously discussed,
three genera were found to be differentially abundant in the same period, including Methanobrevibacter,
Fusobacterium, and a genus within the Ruminococcaceae family. At the genus level, it is hard to state
whether these are positive effects, as a species within these genera can either act in a commensal
or beneficial fashion, or can have adverse effects for the host. Interestingly, the genus Romboutsia
showed a positive correlation with the expression of the cell maturation marker CD80/86 on cDC1
cells (Figure S9). This may imply that Romboutsia contributes to the maturation of the (innate) immune
system. Several Romboutsia spp. are commensals of the mammalian GI tract and have been shown
to be flexible anaerobes that are adapted to the small intestine [63,64]. As for the immune system,
the increased production of the anti-inflammatory cytokine IL-10 by MLN cells, and the decreased
production of TNFα by PBMCs, suggest an anti-inflammatory effect. However, it should be noted that
only a small number of animals were sampled and that the level of LPS induced IL-10 produced by
MLN cells was relatively low (0–61 pg/mL). Nevertheless, these results are in line with other in vivo
studies that showed limited or no effects of yeast-derived β-glucans on the (mucosal) immune system
or vaccination response [58,65–67].
Taken together, this study reinforces that the pre-weaning period constitutes a window of
opportunity to alter the immune system through diet, which may set the stage for immune homeostasis
and subsequent host–microbial interaction. However, the observed changes induced by dietary
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β-glucans were modest, and any long-lasting health effects of yeast-derived β-glucans remain to
be elucidated.
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